Ajanta Pharma announced that the Board of Directors of the Company at its meeting held on 3 November 2025, inter alia, have recommended the interim dividend of Rs 28 per equity Share (i.e. 1400%) , subject to the approval of the shareholders.Powered by Capital Market - Live News

Net profit of Ajanta Pharma rose 20.19% to Rs 260.19 crore in the quarter ended September 2025 as against Rs 216.48 crore during the previous quarter ended September 2024. Sales rose 14.08% to Rs 1353.73 crore in the quarter ended September 2025 as against Rs 1186.64 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales1353.731186.64 14 OPM %24.2226.22 - PBDT383.78324.63 18 PBT340.81290.24 17 NP260.19216.48 20 Powered by Capital Market - Live News

Ajanta Pharma will hold a meeting of the Board of Directors of the Company on 3 November 2025.Powered by Capital Market - Live News

Ajanta Pharma has allotted 23,525 equity shares under ESOP on 28 July 2025. In view of the above, the paid-up capital of the Company stands increased to Rs. 24,98,71,248 consisting of 12,49,35,624 equity shares of Rs. 2/- each. Powered by Capital Market - Live News

Net profit of Ajanta Pharma rose 3.89% to Rs 255.34 crore in the quarter ended June 2025 as against Rs 245.77 crore during the previous quarter ended June 2024. Sales rose 13.78% to Rs 1302.65 crore in the quarter ended June 2025 as against Rs 1144.92 crore during the previous quarter ended June 2024. ParticularsQuarter EndedJun. 2025Jun. 2024% Var. Sales1302.651144.92 14 OPM %26.9728.85 - PBDT372.42356.09 5 PBT331.13322.12 3 NP255.34245.77 4 Powered by Capital Market - Live News